PolyICLC

DRUG5 trials

Sponsors

Craig L Slingluff, Jr, University of Virginia

Conditions

Advanced MelanomaMelanomaMetastatic MelanomaMucosal MelanomaOcular MelanomaUveal Melanoma

Early Phase 1

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

RecruitingNCT06472661

University of VirginiaAdvanced Melanoma

Start: 2024-09-27End: 2026-08-31Target: 11Updated: 2025-11-20

Phase 1

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

CompletedNCT02126579

Craig L Slingluff, JrMelanoma, Metastatic Melanoma, Mucosal Melanoma

Start: 2014-05-01End: 2021-05-05Updated: 2024-02-28

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

TerminatedNCT02425306

Craig L Slingluff, JrMelanoma

Start: 2015-05-12End: 2018-01-08Updated: 2023-10-30

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

CompletedNCT03617328

Craig L Slingluff, JrMelanoma

Start: 2018-11-13End: 2024-01-19Updated: 2024-02-06

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

CompletedNCT04364230

Craig L Slingluff, JrMelanoma, Ocular Melanoma, Uveal Melanoma

Start: 2020-09-28End: 2024-03-14Updated: 2024-07-16

Related Papers

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

2026-03-03

Adjuvant polypeptide vaccines for high-risk uveal melanoma.

Journal of Clinical Oncology2023-06-013 citations

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

Journal for ImmunoTherapy of Cancer2021-08-0158 citations

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

Journal for ImmunoTherapy of Cancer2020-04-0132 citations

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.

Journal of Clinical Oncology2018-05-203 citations